PeptideStack
5.2kquestions
20kanswers
220users

Is 97.6% a realistic purity ceiling for survodutide given its chain length?

Asked 27 Jun 2026Modified 19 days agoViewed 7.8k times
13

The particulars: 97.6% · survodutide.

I would like the arithmetic checked rather than the conclusion asserted.

I have deliberately not used an online calculator because I want to be able to check the result.

Can someone show the working rather than just the answer?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

833 questions
hplc
hplc

Reverse-phase high-performance liquid chromatography, the workhorse purity method. Column chemistry, mobile-phase choice, gradient slope,…

503 questions
peptide-mapping
peptide-mapping

Enzymatic digestion followed by LC-MS/MS to confirm sequence rather than just mass. The method that catches a scrambled sequence or a D-amino-acid…

103 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
LM
askedleonid_marchuk19k2727 Jun 2026

5 Answers

Accepted answer first, then by votes
51

Accepted answer

97.6 per cent is at the top of what stepwise synthesis delivers on a chain this long, and it is reachable rather than fictional. Every coupling is high-yielding and none is quantitative, so the deletion and truncation sequences that survive purification are what occupies the remaining 2.4 per cent. Above roughly 98 per cent you are fighting the purification rather than the synthesis, which is why a 97.6 per cent figure on survodutide deserves a method question — column, gradient, wavelength — rather than either belief or dismissal.

Purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

The relevant detail is that mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.

The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
TG
answered · acceptedtandem_gradient61k24811 Jul 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
20

Start from what the detector sees, because that tells you what the number means.

Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.

It helps to be literal here: mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
DS
answeredDr_Ravi_Selvarajah35k1379 Jul 2026
14

The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The part that matters: buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

One qualification: achieving purity above roughly 98 per cent on a 30-residue peptide is fighting the chemistry of synthesis, not the quality of the purification.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
NN
answerednine_point_nine60k1487 Jul 2026
12

Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.

Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.

If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.

shareimprove this answerflag
DC
answeredDr_Idris_Coulibaly33k1375 Jul 2026
8Adding a vote because this deserves more of them. – Dr_Hanne_Solberg 8 months ago
Any reason to prefer ion chromatography over fluorine NMR for the counter-ion here? – tare_and_weigh 7 days ago
add a comment
11

Mechanically, reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.

In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.

shareimprove this answerflag
TG
answeredtandem_gradient61k2483 Jul 2026
6Confirming from the other direction: I ignored the method section once and paid for it. – second_lot 2 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.